Robin L. Gabriels

Robin L. Gabriels

Auto-generated profile, based on publicly available information

Robin L. Gabriels

Department of Psychiatry and Pediatrics University of Colorado School of Medicine Aurora Colorado USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
RGRobin L. Gabriels
Robin L. Gabriels
ZPZhaoxing Pan
Zhaoxing Pan
BDBriar Dechant
Briar Dechant
JAJohn A. Agnew
John A. Agnew
NBNatalie Brim
Natalie Brim
GMGary Mesibov
Gary Mesibov

7 June 2017 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
F(for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)
for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)
JBJamie Brenner
Jamie Brenner
ZPZhaoxing Pan
Zhaoxing Pan
CMCarla Mazefsky
Carla Mazefsky
KSKahsi A. Smith
Kahsi A. Smith
RGRobin Gabriels
Robin Gabriels

19 June 2012 in Autism Research and Treatment
Verified
Journal Article
Open access
PDF file
RGRobin L. Gabriels
Robin L. Gabriels
JAJohn A. Agnew
John A. Agnew
CBCarol Beresford
Carol Beresford
MMMary Ann Morrow
Mary Ann Morrow
GMGary Mesibov
Gary Mesibov
MWMarianne Wamboldt
Marianne Wamboldt
Pediatric patients with autism spectrum disorders (ASD) and/or intellectual disabilities (ID) are at greater risk for psychiatric hospitalization compared to children with other disorders. However, general psychiatric hospital environments are not adapted for the unique learning styles, needs, and abilities of this population, and there are few specialized hospital-based psychiatric care programs in the United States. This paper compares patient outcomes from a specialized psychiatric hospital program developed for pediatric patients with an ASD and/or ID to prior outcomes of this patient population in a general psychiatric program at a childrens hospital. Record review data indicate improved outcomes for patients in the specialized program of reduced recidivism rates (12% versus 33%) and decreased average lengths of inpatient stay (as short as 26 days versus 45 days). Available data from a subset of patients (𝑛=43) in the specialized program showed a decrease in irritability and hyperactivity behaviors from admission to discharge and that 35 previously undetected ASD diagnoses were made. Results from this preliminary study support specialized psychiatric care practices with this population to positively impact their health care outcomes.

10 November 2015 in Molecular Autism
Verified
Journal Article
Open access
PDF file
F(for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)
for the Autism and Developmental Disorders Inpatient Research Collaborative (ADDIRC)
MSMatthew Siegel
Matthew Siegel
KSKahsi A. Smith
Kahsi A. Smith
CMCarla Mazefsky
Carla Mazefsky
RGRobin L. Gabriels
Robin L. Gabriels
SSSusan L. Santangelo
Susan L. Santangelo
Individuals severely affected by autism spectrum disorder (ASD), including those with intellectual disability, expressive language impairment, and/or self-injurious behavior (SIB), are underrepresented in the ASD literature and extant collections of phenotypic and biological data. An understanding of ASD’s etiology and subtypes can only be as complete as the studied samples are representative. The Autism Inpatient Collection (AIC) is a multi-site study enrolling children and adolescents with ASD aged 4–20 years admitted to six specialized inpatient psychiatry units. Enrollment began March, 2014, and continues at a rate of over 400 children annually. Measures characterizing adaptive and cognitive functioning, communication, externalizing behaviors, emotion regulation, psychiatric co-morbidity, self-injurious behavior, parent stress, and parent self-efficacy are collected. ASD diagnosis is confirmed by the Autism Diagnostic Observation Schedule – 2 (ADOS-2) and extensive inpatient observation. Biological samples from probands and their biological parents are banked and processed for DNA extraction and creation of lymphoblastoid cell lines. Sixty-one percent of eligible subjects were enrolled. The first 147 subjects were an average of 12.6 years old (SD 3.42, range 4–20); 26.5 % female; 74.8 % Caucasian, and 81.6 % non-Hispanic/non-Latino. Mean non-verbal intelligence quotient IQ = 70.9 (SD 29.16, range 30–137) and mean adaptive behavior composite score = 55.6 (SD 12.9, range 27–96). A majority of subjects (52.4 %) were non- or minimally verbal. The average Aberrant Behavior Checklist - Irritability Subscale score was 28.6, well above the typical threshold for clinically concerning externalizing behaviors, and 26.5 % of the sample engaged in SIB. Females had more frequent and severe SIB than males. Preliminary data indicate that the AIC has a rich representation of the portion of the autism spectrum that is understudied and underrepresented in extant data collections. More than half of the sample is non- or minimally verbal, over 40 % have intellectual disability, and over one quarter exhibit SIB. The AIC is a substantial new resource for study of the full autism spectrum, which will augment existing data on higher-functioning cohorts and facilitate the identification of genetic subtypes and novel treatment targets. The AIC investigators welcome collaborations with other investigators, and access to the AIC phenotypic data and biosamples may be requested through the Simons Foundation ( www.sfari.org ).

1 May 2013 in Biological Psychology
Verified
Journal Article
Closed access
RGRobin L. Gabriels
Robin L. Gabriels
JAJohn A. Agnew
John A. Agnew
ZPZhaoxing Pan
Zhaoxing Pan
KHKatherine D. Holt
Katherine D. Holt
ARAnn Reynolds
Ann Reynolds
MLMark L. Laudenslager
Mark L. Laudenslager

14 January 2019 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
PDF file
ZPZhaoxing Pan
Zhaoxing Pan
DGDouglas A. Granger
Douglas A. Granger
NGNoémie A. Guérin
Noémie A. Guérin
ASAmy Shoffner
Amy Shoffner
RGRobin L. Gabriels
Robin L. Gabriels
We aimed to determine whether results of our prior randomized control trial [RCT; NCT02301195, (1)] of Therapeutic Horseback Riding (THR) for children and adolescents with autism spectrum disorder (ASD) could be replicated at a different riding center and if treatment effects also included differences in the expression of associations between problem behavior and the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Participants with ASD (N = 16) ages 6-16 years were randomized by nonverbal intelligence quotient to either a 10-week THR group (n = 8) or no horse interaction barn activity (BA) control group (n = 8). Outcome measures were a standard speech-language sample and caregiver-report of aberrant and social behaviors. Participants' saliva was sampled weekly at a consistent afternoon time immediately pre- and 20 min' post-condition (later assayed for cortisol). Intent-to-treat analysis revealed that compared to controls, THR participants had significant improvements in hyperactivity, and social awareness, and significant improvements at the 0.1 significance level in irritability and social communication behaviors. There were no significant improvements in number of words or new words spoken during the standard language sample. Linear mixed effects model analysis indicated that greater weekly pre-lesson irritability levels were associated with smaller post-lesson reduction in salivary cortisol levels, and greater weekly pre-lesson hyperactivity levels were associated with smaller cortisol reduction in the THR group, but not in the BA control group. The findings represent a partial replication of prior results (1), extend prior observations to include THR effects on biobehavioral relationships and suggest that cortisol could be a target mediator for THR effects on irritability and hyperactivity behaviors in youth with ASD. Clinical Trial Registration: Trial of Therapeutic Horseback Riding in Children and Adolescents with Autism Spectrum Disorder; http://clinicaltrials.gov, identifier: NCT02301195